Cargando…

New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation

BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could p...

Descripción completa

Detalles Bibliográficos
Autores principales: Gunduz, Mithat, Argikar, Upendra A., Cirello, Amanda L., Dumouchel, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350207/
https://www.ncbi.nlm.nih.gov/pubmed/29886840
http://dx.doi.org/10.2174/1872312812666180611113656
_version_ 1783390407548207104
author Gunduz, Mithat
Argikar, Upendra A.
Cirello, Amanda L.
Dumouchel, Jennifer L.
author_facet Gunduz, Mithat
Argikar, Upendra A.
Cirello, Amanda L.
Dumouchel, Jennifer L.
author_sort Gunduz, Mithat
collection PubMed
description BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose ma-jor developability concerns. To date, multiple in vitro assays have been published to assess the risk asso-ciated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safe-ty remains poor. METHODS: In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as “safe,” “warning,” or “withdrawn” with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key interme-diates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s). RESULTS: Our results were in line with reported values in the literature. Our assay could be used in discov-ery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented. CONCLUSION: While the compounds tested from “withdrawn” and “warning category” all formed the glu-tathione adduct in buffer, none from “safe” category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative alde-hyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest.
format Online
Article
Text
id pubmed-6350207
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-63502072019-02-22 New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation Gunduz, Mithat Argikar, Upendra A. Cirello, Amanda L. Dumouchel, Jennifer L. Drug Metab Lett Article BACKGROUND: Acyl glucuronides of xenobiotics have been a subject of wide interest from the pharmaceutical industry with respect to biochemical reactivity, hepatic disposition, and enterohepatic cir-culation. The reactivity and lack of stability of an acyl glucuronide for a clinical candidate could pose ma-jor developability concerns. To date, multiple in vitro assays have been published to assess the risk asso-ciated with acyl glucuronides. Despite this fact, the translation of these findings to predicting clinical safe-ty remains poor. METHODS: In the present investigation, we aimed to provide simplified in vitro strategy to understand the bioactivation potential of acyl glucuronides of 10 commercial, carboxylic acid containing drugs that have been categorized as “safe,” “warning,” or “withdrawn” with respect to their marketed use. Acyl migration was measured as a function of the number of peaks observed in LC-MSn analysis. In addition, we carried out reactive intermediate trapping studies with glutathione and methoxylamine to identify the key interme-diates in the transacylation bioactivation and glycation pathways, respectively. We also conducted reaction phenotyping with recombinant UDP-glucuronosyltransferase (UGT) Supersomes® to investigate if the formation of acyl glucuronides could be linked to specific UGT isoform(s). RESULTS: Our results were in line with reported values in the literature. Our assay could be used in discov-ery research where half-life calculation completely eliminated the need to chemically synthesize the acyl glucuronide standard for risk assessment. We captured our results for risk assessment in a flow chart to simplify the various complex in vitro techniques historically presented. CONCLUSION: While the compounds tested from “withdrawn” and “warning category” all formed the glu-tathione adduct in buffer, none from “safe” category formed the glutathione adduct. In contrast, none of the compounds tested from any category formed methoxylamine conjugate, a reaction with putative alde-hyde moiety formed via acyl migration. These results, highly favor the nucleophilic displacement as a cause of the reactivity rather than the acyl migration via aldehyde formation. The workflow presented could also be applied in the discovery setting to triage new chemical entities of interest. Bentham Science Publishers 2018-12 2018-12 /pmc/articles/PMC6350207/ /pubmed/29886840 http://dx.doi.org/10.2174/1872312812666180611113656 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Gunduz, Mithat
Argikar, Upendra A.
Cirello, Amanda L.
Dumouchel, Jennifer L.
New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title_full New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title_fullStr New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title_full_unstemmed New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title_short New Perspectives on Acyl Glucuronide Risk Assessment in Drug Discovery: Investigation of In vitro Stability, In situ Reactivity, and Bioactivation
title_sort new perspectives on acyl glucuronide risk assessment in drug discovery: investigation of in vitro stability, in situ reactivity, and bioactivation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350207/
https://www.ncbi.nlm.nih.gov/pubmed/29886840
http://dx.doi.org/10.2174/1872312812666180611113656
work_keys_str_mv AT gunduzmithat newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation
AT argikarupendraa newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation
AT cirelloamandal newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation
AT dumoucheljenniferl newperspectivesonacylglucuronideriskassessmentindrugdiscoveryinvestigationofinvitrostabilityinsitureactivityandbioactivation